[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353723-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353723-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","alterations-in-the-ctrb2-gene-and-response-to-chemotherapy-in-pancreatic-cancer","Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer","","Pancreatic ductal adenocarcinoma remains highly fatal due in part to treatment resistance. Prior work reported a functional germline deletion overlapping exon 6 of CTRB2 (CTRB2ex6), producing a nonfunctional truncated chymotrypsin protein and inducing endoplasmic reticulum stress. This retrospective study evaluates whether CTRB2ex6 deletions relate to chemotherapy response, time to progression, and overall survival in PDAC patients using two independent cohorts and Cox proportional hazards models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/alterations-in-the-ctrb2-gene-and-response-to-chemotherapy-in-pancreatic-cancer/353723/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/alterations-in-the-ctrb2-gene-and-response-to-chemotherapy-in-pancreatic-cancer/353723.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What prior genetic finding motivates this study?","Question",{"text":63,"@type":64},"A functional germline deletion overlapping exon 6 of CTRB2 (CTRB2ex6) was previously linked to a PDAC risk locus and is associated with a nonfunctional truncated chymotrypsin protein that induces endoplasmic reticulum stress.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were associations between CTRB2ex6 deletions and outcomes tested?",{"text":68,"@type":64},"The study assessed CTRB2ex6 deletion status in two independent PDAC cohorts and used Cox proportional hazard modeling to analyze associations with overall survival and time-to-progression.",{"name":70,"@type":61,"acceptedAnswer":71},"Did CTRB2ex6 deletions affect chemotherapy response or survival?",{"text":72,"@type":64},"No significant clinical impact on chemotherapy response or overall survival was observed by CTRB2 deletion status, though a longer median time-to-progression was noted in chemotherapy-treated carriers without statistical significance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353723,1790491074,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","OPEN ACCESS  \nCitation: Jazieh K, Carlson EE, Siddiqui Z, Connelly KE, Zhong J, Hoskins JW, et al. (2026) Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer. PLoSOne 21(2): e0343022. [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0343022](journal.pone.0343022)  \nEditor: Giuseppe Novelli, Universita degli Studi  \ndi Roma Tor Vergata, ITALY Received: September 27, 2025  \nAccepted: January 30, 2026  \nPublished: February 19, 2026  \nCopyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.  \nData availability statement: Due to ethical restrictions and a binding legal agreement, individual-level data cannot be deposited ina public repository or shared as part of this submission. Public release of these data would violate the protocol approved by the  \nRESEARCH ARTICLE  \nAlterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer  \nKhalid Jazieh1, Erin E. Carlson2, Zafar Siddiqui3, Katelyn E. Connelly4, Jun Zhong4, Jason W. Hoskins4, Kari G. Rabe2, MAYO-RGC Project Generation, Regeneron Genetics Center, Ann L. Oberg5, Hugues Sicotte5, Ryan M. Carr1,  \nLaufey T. Amundadottir4, Samuel O. Antwi6*  \n1 Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, United States of America,  \n2 Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, United States of America, 3 Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America, 4 Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 5 Department of Quantitative Health Sciences, Computational Biology, Mayo Clinic, Rochester, Minnesota, United States of America, 6 Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Jacksonville, Florida, United States of America  \n* [Antwi.samuel@mayo.edu](Antwi.samuel@mayo.edu)  \nAbstract  \nBackground  \nPancreatic ductal adenocarcinoma (PDAC) remains a highly fatal malignancy due partly to treatment resistance in many patients. We previously identified a functional germline deletion overlapping exon 6 of CTRB2 (CTRB2ex6) at a PDAC genomewide risk locus on chr16q23 .1. This variant leads to a nonfunctional truncated chymotrypsin protein that accumulates intracellularly and induces endoplasmic reticulum stress. Here, we performed a retrospective study to determine whether CTRB2ex6 deletions are associated with response to chemotherapy, time to cancer progression, or overall survival (OS) in PDAC patients.  \nMethods  \nThe study included CTRB2 genotype data from two independent PDAC cohorts (Cohort 1: n = 633; Cohort 2: n = 3,896) . We examined associations between CTRB2ex6 deletion status and OS and time-to-progression (TTP) using Cox proportional hazard modeling. TTP was also evaluated in a subset of chemotherapy-treated patients in Cohort 1 (n = 263) to determine the impact of CTRB2ex6 deletion status on chemotherapy response.  \nResults  \nCTRB2ex6 deletions were found in 20% of patients in both cohorts combined (19% in Cohort 1, and 21% in Cohort 2) . No significant difference was observed in OS  \nPLOS One | [https://doi.org/10.1371/journal.pone.0343022](https://doi.org/10.1371/journal.pone.0343022) February 19, 2026 1 / 13  \nInstitutional Review Board and the terms of the contractual agreement. The underlying data are jointly owned by a third party (Regeneron Genetics Center), which has imposed these restrictions. Aggregate summary statistics maybe made available to qualified investigators upon reasonable request to the Mayo Clinic Institutional Review Board ([irbe@mayo.","cbCaivepyyWsuAPc","https://ap.wps.com/l/cbCaivepyyWsuAPc","pdf",623001,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Discussion\n# Introduction\n# Funding and disclosures\n# Abbreviations","[{\"question\":\"What prior genetic finding motivates this study?\",\"answer\":\"A functional germline deletion overlapping exon 6 of CTRB2 (CTRB2ex6) was previously linked to a PDAC risk locus and is associated with a nonfunctional truncated chymotrypsin protein that induces endoplasmic reticulum stress.\"},{\"question\":\"How were associations between CTRB2ex6 deletions and outcomes tested?\",\"answer\":\"The study assessed CTRB2ex6 deletion status in two independent PDAC cohorts and used Cox proportional hazard modeling to analyze associations with overall survival and time-to-progression.\"},{\"question\":\"Did CTRB2ex6 deletions affect chemotherapy response or survival?\",\"answer\":\"No significant clinical impact on chemotherapy response or overall survival was observed by CTRB2 deletion status, though a longer median time-to-progression was noted in chemotherapy-treated carriers without statistical significance.\"}]","Alterations in the CTRB2 gene and response to chemotherapy in pancreatic cancer | PDF",1790106953,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7e593af6d5daa3b8b4e353c5465e9f0.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36c216363a2aaaac046d057587878bbb.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6df57c1ca120af87ae7fca98ab96220.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f62bcd65f10714662fcf3a15f6d6683e.webp",980,1268]